Overview

Effect of Renal Impairment on the Pharmacokinetics of NN9535

Status:
Completed
Trial end date:
2010-07-26
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S